Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 28Small Cell Lung Carcinoma 24Fallopian Tube Neoplasms 12Uterine Cervical Neoplasms 8Carcinoma, Ovarian Epithelial 8Neuroblastoma 7Lung Neoplasms 6Sarcoma 3Neoplasms 3Retinoblastoma 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Ganglioneuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1SCLC 1Rhabdomyosarcoma 1Retinal Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Localized Extraskeletal Ewing Sarcoma 1Leukemia 1Eye Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Carboplatin 17Cisplatin 14Paclitaxel 12Pemetrexed 11pembrolizumab 9Gemcitabine 7Docetaxel 6Sorafenib 5osimertinib 4durvalumab 4130-nm albumin-bound paclitaxel 4padeliporfin 3cabozantinib 3atezolizumab 3Taxes 3Radiotherapy 3Mitomycin 3Magnetic Resonance Spectroscopy 3Cetuximab 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2Sunitinib 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma × Topotecan × Clear all
NCT01840943 2015-12-23

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Xian-Janssen Pharmaceutical Ltd.

Phase 3 Terminated
32 enrolled 13 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡